Viro - viro - Ravimiamet

krka, d.d., novo mesto - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+25mg 90tk; 100mg+25mg 14tk; 100mg+25mg 60tk; 100mg+25mg 7tk; 100mg+25mg 50tk; 100mg+25mg 56tk; 100mg+25mg 112tk; 100mg+25mg 100tk; 100mg+25mg 84tk

Viro - viro - Ravimiamet

virbac - amoksitsilliin - suukaudse lahuse pulber - 500mg 1g 2000g 1tk; 500mg 1g 1000g 1tk; 500mg 1g 100g 1tk

Viro - viro - Ravimiamet

virbac - amoksitsilliin - suukaudse lahuse pulber - 500mg 1g 1500g 1tk; 500mg 1g 100g 1tk; 500mg 1g 1000g 1tk; 500mg 1g 2000g 1tk; 500mg 1g 3000g 1tk; 500mg 1g 500g 1tk

Viro - viro - Ravimiamet

glaxosmithkline dungarvan limited - paratsetamool+kloorfenamiin+pseudoefedriin+dekstrometorfaan - suukaudse lahuse pulber - 1000mg+4mg+60mg+30mg 6tk

Viro - viro - Ravimiamet

actavis group ptc ehf. - paratsetamool - õhukese polümeerikattega tablett - 500mg 30tk; 500mg 10tk; 500mg 20tk

Euroopan unioni - viro - EMA (European Medicines Agency)

eli lilly nederland b.v. - insuliin lispro - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel. suhkurtõve ravi täiskasvanutel.

Euroopan unioni - viro - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - erütematoosne luupus, süsteemne - immunosupressandid - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Viro - viro - Ravimiamet

ideal trade links uab - kvetiapiin - õhukese polümeerikattega tablett - 25mg 60tk; 25mg 10tk; 25mg 30tk; 25mg 100tk

Euroopan unioni - viro - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosupressandid - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Euroopan unioni - viro - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - koliit, haavandiline - immunosupressandid - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.